The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid ...

The US FDA has issued new guidance on ways to expand development of non-opioid treatment options for chronic pain.

Journavx (suzetrigine) 50 mg oral tablets, the first-in-class non-opioid analgesic for moderate to severe acute pain, was ...

Advisory committee meetings help FDA scientists make decisions and increase public understanding of drug regulation, and ...

The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and ...

By Stephanie Brown HealthDay ReporterWEDNESDAY, Sept. 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration ...

In today's Morning Rounds newsletter, NIH is finally spending down its coffers, FDA eyes tighter regulations on chatbots for ...

Rapid scientific advances are accelerating the development of medical innovations, from personalized treatments to curative ...

The FDA has issued new draft guidance to promote safe and effective non-opioid treatments, and to curb prescription-related opioid misuse. In a press release, the FDA said that the cornerstone of the ...

Last month, Prasad returned to his role overseeing vaccine, gene therapy and blood product regulation at the FDA, a little ...